We are studying whether 6 months of immunotherapy after surgery is as effective as 12 months for patients with high-risk malignant melanoma. This could help determine the best treatment duration for better outcomes.
Health conditions and diseases that the clinical trial is designed to study and treat.
Cutaneous malignant melanoma is a serious form of skin cancer that develops from melanocytes, the cells that produce pigment in the skin. It can appear as a new or changing mole and may spread to other parts of the body if not treated early.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
